Related Experiment Video
Updated: Jun 28, 2026
16:56
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Perception and practice of sublingual immunotherapy among practicing allergists
Mark H Tucker1, Michael S Tankersley,
1Department of Allergy and Immunology, Naval Medical Center, San Diego, California 92106, USA. mhtucker@pol.net
Summary
Most US allergists surveyed perceive sublingual immunotherapy (SLIT) as safe and effective, but few currently use it due to lack of FDA approval. Many would adopt SLIT if approved, especially for allergic rhinitis.
Area of Science:
- Allergy and Immunology
- Immunotherapy Research
- Clinical Practice Surveys
Background:
- Limited data exists on the current use, products, dosing, and perceived effectiveness of sublingual immunotherapy (SLIT) in the United States.
- Understanding current SLIT adoption is crucial for advancing allergy treatment options.
Purpose of the Study:
- To investigate the perceptions and current usage patterns of SLIT among practicing allergists in the United States.
- To identify barriers to SLIT adoption and potential future use.
Main Methods:
- An electronic survey was distributed to all practicing allergists affiliated with the American College of Allergy, Asthma and Immunology (ACAAI) in March 2007.
- The survey collected data on SLIT usage, reasons for non-use, and perceived efficacy compared to subcutaneous immunotherapy (SCIT).
Main Results:
- A 25.7% response rate (828/3,217) was achieved, with 92.5% of respondents practicing in the US.
- Lack of Food and Drug Administration (FDA) approval was the primary reason for not using SLIT (61.7%).
- Only 5.9% of US allergists reported using SLIT, though 65.7% would use it for allergic rhinitis if FDA-approved. Most perceived SLIT as effective as or more effective than SCIT.
Conclusions:
- Despite low current usage (5.9%), a majority of surveyed US allergists consider sublingual immunotherapy (SLIT) safe and effective.
- FDA approval is a significant factor influencing the adoption of SLIT, with widespread interest in using it for allergic rhinitis and other conditions if approved.
